Grassley briefs Dems on outstanding FDA issues

Share this article:
Outgoing Senate Finance Committee chairman Chuck Grassley (R-IA) has written Democrat Senate HELP Committee leaders with a laundry list of FDA shortcomings that he hopes they will address in the new session beginning in January. In a letter, he summarized “systemic” FDA problems, such as drug safety, scientific morale, and a “too cozy” relationship with the industries it regulates.

Grassley complained about FDA senior officials who “disregarded and downplayed important concerns and warnings from its own scientists,” and their pressures to have scientists change their findings or conclusions regarding a safety or efficacy issue.

The day after Grassley sent his letter, incoming HELP Committee chairman Edward M. Kennedy (D-MA) took the opportunity of the committee's last, lame-duck session to lambaste their impact on the FDA.

“Science has, too often, had to take a backseat at the very agency which should be setting the standard for objectivity and integrity,” he said.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...